U.S. In-vitro Fertilization Market (2026 - 2033)

U.S. In-vitro Fertilization Market Summary

The U.S. in vitro fertilization market size was valued at USD 5.9 billion in 2025 and is projected to grow from USD 6.2 billion in 2026 to USD 8.0 billion, at a CAGR of 3.7% from 2026 to 2033. The rising prevalence of infertility among couples is driving the growth of the U.S. IVF market. According to the U.S. Centers for Disease Control and Prevention (CDC), in a report published in December 2025, 1.6% of women aged 20-49 years in the U.S. had used in vitro fertilization (IVF) or other assisted reproductive technology (ART) procedures during 2022-2023, highlighting the utilization of assisted reproductive treatments to address fertility challenges.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, product substitutes, and regional expansion.

The industry is experiencing continued innovation in embryo assessment, with AI-based tools supporting embryo selection and laboratory decision-making. For instance, in May 2026, Alife Health received FDA clearance for Embryo Predict, an AI-powered software tool that analyzes images of blastocyst-stage embryos and provides additional information to fertility specialists evaluating embryos for transfer or freezing. The product was supported by a randomized, multicenter clinical trial involving 440 patients across seven U.S. clinics. This development highlights the growing role of AI-enabled software in IVF laboratory workflows.

To learn more about this report, Download Free Sample Report

Fertility care providers are expanding their clinic networks through acquisitions and affiliations, supporting their geographic reach and access to reproductive medicine services. For instance, in February 2026, INVO Fertility completed its acquisition of Family Beginnings, an Indiana-based fertility clinic. The transaction expanded INVO Fertility’s clinic portfolio and strengthened its presence in the Midwest. Such transactions illustrate how providers are using acquisitions to broaden their service networks and patient access.

Regulatory changes affecting insurance coverage are influencing patients’ access to IVF services and may affect treatment affordability. For instance, in January 2026, California’s Senate Bill 729 coverage requirements took effect for applicable large-group health insurance policies issued, amended, or renewed on or after January 1. The law requires coverage for infertility diagnosis and treatment, including IVF, while applicable small-group plans must offer such coverage. These requirements may improve access to treatment for eligible insured patients, although coverage depends on plan eligibility and applicable exclusions.

Companies are expanding fertility-care offerings through digital services and new laboratory technologies, creating additional ways for patients to access treatment and support. For instance, in March 2026, Sesame announced a fertility-care program with Costco and IVI RMA, offering virtual consultations, care coordination, medication management, and referrals to in-person fertility specialists. The program adds a digital access pathway for patients beginning fertility treatment and may help connect them with specialized IVF services.

Fertility providers are opening clinics in new locations to bring reproductive services closer to patients and reduce travel requirements during treatment. For instance, in May 2026, Columbia University Fertility Center announced the opening of a new clinic in Teaneck, New Jersey, which began operating in February 2026. The clinic offers fertility evaluations, IVF-related services, embryo genetic testing, and treatment monitoring, extending the center’s reach to patients in northern New Jersey. This expansion illustrates how providers are broadening their local presence to improve geographic access to fertility care.

Analyst Perspective

The market’s growth potential is increasingly linked to the ability of fertility providers to improve treatment success rates, optimize laboratory processes, and manage the rising complexity of ART procedures. Embryo assessment systems, AI-enabled decision-support tools, and advanced cryopreservation technologies are becoming important areas of differentiation for fertility clinics, creating demand for specialized equipment, software, and laboratory consumables. From a competitive standpoint, suppliers offering integrated ART solutions and technologies that improve workflow efficiency may be better positioned to secure long-term relationships with fertility centers. However, the adoption of advanced technologies remains dependent on clinics’ investment capacity, clinical validation, and compatibility with existing laboratory infrastructure. High out-of-pocket treatment costs and inconsistent insurance coverage also constrain patient volumes and limit the adoption of premium fertility services, making affordability and demonstrable clinical value important factors shaping future market opportunities.

Procedure Type Insights

The fresh non-donor segment accounted for the largest market share of 46.6% in 2025. Fresh cycles are often perceived as more cost-effective due to potentially requiring fewer treatment cycles to achieve a successful pregnancy. In addition, some insurance plans may cover fresh cycles, further supporting demand for fresh non-donor IVF. For instance, in October 2025, US Fertility reported findings from a randomized, double-blind clinical trial involving 400 patients undergoing egg retrieval. The study found comparable reproductive outcomes among patients with proceeded fresh embryo transfer despite differences in postoperative pain-management protocols, providing further clinical evidence on fresh-transfer outcomes.

Frozen donors are expected to register the fastest CAGR during the forecast period, owing to the convenience and flexibility offered by frozen donor eggs. Advances in egg-freezing technology have improved the use of frozen donor eggs in IVF procedures, while egg banks provide recipients with access to donors from different geographic locations and backgrounds. For instance, in March 2026, The World Egg and Sperm Bank launched its Give & Receive program, allowing eligible egg donors to donate eggs to intended parents while preserving a portion of their eggs for their own future use at no cost. This initiative highlights the continued expansion of egg donation and fertility preservation services.

Instruments Insights

The culture media segment dominated the market and accounted for the largest share in 2025. This is attributed to factors such as the availability of funding and an increase in research activities to improve culture media. For instance, in January 2025, FUJIFILM Irvine Scientific announced an agreement to sell its Medical Media Business Unit to Astorg, expanding Astorg’s portfolio of products serving the assisted reproductive technology and IVF industry. The transaction reflects continued strategic investment in the IVF medical media sector.

Disposable devices are expected to grow at the fastest CAGR over the forecast period. The growth is attributed to the introduction of disposable devices, including needles, chambers, and slides, by industry players to comply with sterility and regulatory standards. These advancements are anticipated to boost the adoption of disposable IVF devices. Recent innovations in the market include disposable slides for sperm counting, imaging-based systems for tracking and isolating motile sperm, and disposable microchips.

End-use Insights

The fertility clinics segment dominated the market in 2025 and is expected to grow at the fastest CAGR over the forecast period. This is attributable to increasing demand for ART treatments, expansion of specialized fertility services, and the availability of advanced reproductive technologies at dedicated clinics. Fertility clinics provide comprehensive services, including fertility evaluations, ovarian stimulation, egg retrieval, embryo culture, and embryo transfer, supporting patient access to specialized care. For instance, in April 2026, CCRM Fertility announced the opening of its newest clinic in Greenville, South Carolina, expanding its geographic presence and access to specialized fertility care and reproductive services in the region. Such expansions support the availability of dedicated treatment facilities and strengthen the role of fertility clinics in delivering ART procedures.

To learn more about this report, Download Free Sample Report

Hospitals and other segments are expected to grow at a significant CAGR over the forecast period. The cost of providing IVF treatments in hospitals is higher compared to fertility clinics due to the presence of highly skilled physicians and staff for performing these complex procedures. Hospitals also offer access to specialized diagnostic facilities, multidisciplinary medical teams, and laboratory infrastructure required for managing patients with complex fertility needs. In addition, the availability of integrated medical services supports IVF treatment for patients requiring additional clinical monitoring or care for underlying reproductive health conditions.

Key U.S. ENT Endoscopy Company Insights

Some of the key players operating in the market include Merck & Co., Inc., FUJIFILM Irvine Scientific (FUJIFILM Holdings Corporation), Vitrolife and others.

• Merck & Co., Inc., plays a significant role by providing a range of products and services that cater to the needs of fertility clinics and hospitals.

• FUJIFILM Irvine Scientific specializes in providing innovative cell culture media and reagents for the assisted reproductive technology (ART) field, particularly in vitro fertilization (IVF). The company plays a crucial role in the U.S. IVF market by offering a wide range of products and services that support various stages of the IVF process.

Key U.S. In Vitro Fertilization Companies

• Bayer AG

• Cook Medical LLC

• EMD Serono, Inc.

• Ferring B.V.

• FUJIFILM Irvine Scientific (FUJIFILM Holdings Corporation)

• Genea Biomedx

• EMD Serono, Inc. (Merck KGaA)

• Merck & Co., Inc.

• The Cooper Companies, Inc.

• Thermo Fisher Scientific, Inc.

• Vitrolife

• Nova IVF

• RMA Network (Reproductive Medicine Associates)

• U.S. Fertility

Recent Developments

• In October 2026, IVI RMA North America introduced its Artemis technology platform and AiVA AI Assistant, an AI-powered tool designed to provide clinical insights and support personalized patient care in reproductive medicine.

• In January 2025, Gameto received FDA clearance for the Investigational New Drug application for Fertilo, enabling the launch of a U.S. Phase 3 clinical trial for its induced pluripotent stem cell-based approach to egg maturation.

• In January 2025, NewGen IVF announced a strategic acquisition agreement for MicroSort, a sperm-sorting technology that separates X- and Y-chromosome-bearing sperm cells to support selected reproductive applications. The acquisition was completed in February 2025.

• In January 2024, IVI RMA announced the acquisition of the North American Operations of Eugin Group, comprising the Toronto-based TRIO and Boston IVF fertility network. The strategy is aimed at providing evidence-based fertility solutions along with assuring success for a large number of patients.

U.S. In-vitro Fertilization Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global U.S. in-vitro fertilization (IVF) market report based on instruments, procedure type, and end-use:

• Instrument Outlook (Revenue, USD Billion, 2021 - 2033)

  • Disposable Devices

  • Culture Media

    • Cryopreservation Media

    • Embryo Culture Media

    • Ovum Processing Media

    • Sperm Processing Media

  • Capital Equipment

    • Sperm Analyzer Systems

    • Imaging Systems

    • Ovum Aspiration Pumps

    • Micromanipulator Systems

    • Incubators

    • Gas Analyzers

    • Laser Systems

    • Cryosystems

    • Sperm Separation Devices

    • IVF Cabinets

    • Anti-vibration Tables

    • Witness Systems

    • Other

• Procedure Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Fresh Donor

  • Frozen Donor

  • Fresh Non-Donor

  • Frozen Non-Donor

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Fertility Clinics

  • Hospitals & Others Setting

Research Methodology

The U.S. in vitro fertilization market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each U.S. in vitro fertilization segment quantified using the revenue-capture definitions in the table below.

Estimation Model

More Details

This research methodology outlines the process for estimating the size of the U.S. in vitro fertilization (IVF) market from 2021 to 2033. The study covers key instrument categories, including Culture Media, Disposable Devices, and Capital Equipment; procedure types, including Fresh Donor, Frozen Donor, Fresh Non-Donor, and Frozen Non-Donor; and end-use settings, including Fertility Clinics and Hospitals & Other Settings.

The objective is to develop a robust and defensible market estimate by combining bottom-up and top-down approaches, supported by primary industry validation.

A triangulated market-sizing approach was used, combining:

• Bottom-Up Analysis based on IVF treatment cycle volumes, procedure mix, fertility clinic activity, instrument utilization, sales of IVF consumables and equipment, average selling prices, and revenues generated across the value chain.

• Top-Down Analysis using U.S. IVF treatment expenditure, assisted reproductive technology (ART) cycle statistics, fertility treatment spending, healthcare expenditure, insurance coverage, patient demographics, and revenues reported by IVF service providers and product manufacturers.

• Primary Research with fertility clinic operators, reproductive endocrinologists, embryologists, IVF laboratory managers, medical device manufacturers, culture media suppliers, distributors, industry consultants, and other market participants.

Step-by-Step Market Estimation Process

IVF Treatment Cycle Volume and Procedure Revenue Model

This model estimates the market size based on the number of IVF treatment cycles performed annually and the average revenue generated per treatment cycle.

Step 1: Historical U.S. IVF treatment cycle volumes from 2021 to 2025 were collected from national ART registry reports, government databases, fertility societies, clinic disclosures, published research, and other relevant industry sources.

Step 2: Treatment cycles were classified by procedure type, including Fresh Donor, Frozen Donor, Fresh Non-Donor, and Frozen Non-Donor. Cycle volumes were estimated using available ART statistics, donor egg utilization, embryo transfer data, fertility clinic reports, and primary interviews.

Step 3: Average revenue per IVF cycle was estimated using treatment charges, ovarian stimulation and monitoring costs, egg retrieval, fertilization procedures, embryo culture, embryo transfer, cryopreservation, laboratory services, and other relevant treatment-related charges.

Step 4: Market size was calculated using:

Number of IVF Treatment Cycles × Average Revenue per IVF Treatment Cycle

Step 5: Procedure-level estimates were aggregated and reconciled with national IVF expenditure and available industry revenue data to establish the overall U.S. market size.

Step 6: Historical and forecast growth rates were incorporated based on ART treatment volumes, infertility prevalence, patient age profiles, insurance coverage, treatment affordability, procedure mix, and changes in fertility treatment utilization.

IVF Instrument Revenue Model

This model estimates the market size based on revenues generated by instruments and consumables used during IVF procedures.

Step 1: The market was classified into the following instrument categories:

• Culture Media

• Disposable Devices

• Capital Equipment

Step 2: Product-level information was collected from manufacturer disclosures, product catalogs, regulatory databases, distributor information, company reports, industry databases, and primary interviews.

Step 3: Product demand was estimated using IVF laboratory volumes, treatment cycles, equipment installations, product replacement requirements, consumable usage per cycle, and utilization rates across fertility clinics and hospitals.

Step 4: Average selling prices were estimated using manufacturer pricing information, distributor quotations, procurement benchmarks, product specifications, and primary research.

Step 5: Instrument market revenue was calculated using:

Units Sold × Average Selling Price

For consumables, estimates also considered the number of IVF cycles and the average quantity of products used per cycle. For capital equipment, the model considered installations, replacement purchases, and average equipment prices.

Step 6: Revenue estimates were aggregated across product categories and reconciled with overall market estimates. Forecast assumptions incorporated changes in IVF procedure volumes, laboratory capacity, product replacement cycles, consumable usage, equipment purchases, and technology adoption.

Culture Media Revenue Model

This model estimates market revenues generated by culture media used during different stages of IVF treatment.

Step 1: Culture media demand was assessed across relevant applications, including embryo culture, sperm processing, ovum processing, and cryopreservation.

Step 2: Product utilization was estimated using IVF cycle volumes, laboratory protocols, media requirements per procedure, product usage rates, and information obtained from manufacturers and fertility clinics.

Step 3: Average selling prices were estimated based on product type, packaging, usage volume, supplier pricing, and available procurement benchmarks.

Step 4: Culture media revenue was calculated using:

Volume of Culture Media Sold × Average Selling Price

Step 5: Revenue estimates were aggregated and reconciled with the overall instrument market to maintain consistency and avoid double counting.

Step 6: Forecast assumptions considered changes in IVF cycle volumes, laboratory throughput, media consumption, product pricing, embryo culture practices, and demand for specialized reproductive laboratory consumables.

Disposable Devices Revenue Model

This model estimates market size based on single-use devices used during IVF procedures.

Step 1: Disposable devices were assessed across relevant product categories, including embryo transfer catheters, needles, pipettes, aspiration-related products, and other single-use IVF devices.

Step 2: Product demand was estimated using IVF cycle volumes, the number of procedures performed, device usage per cycle, replacement requirements, and purchasing patterns among fertility clinics and hospitals.

Step 3: Average selling prices were estimated using manufacturer and distributor pricing, procurement information, product specifications, and primary interviews.

Step 4: Market revenue was calculated using:

Number of Disposable Devices Sold × Average Selling Price per Device

Step 5: Product-level revenues were aggregated to determine total disposable device revenue and cross-checked against overall instrument market estimates.

Step 6: Forecast assumptions incorporated IVF procedure volumes, sterility requirements, single-use product preferences, product availability, purchasing patterns, and changes in disposable device utilization.

Capital Equipment Revenue Model

This model estimates market size based on equipment used in IVF laboratories and clinical procedures.

Step 1: Capital equipment was assessed across relevant categories, including incubators, imaging systems, sperm analyzers, micromanipulator systems, ovum aspiration pumps, cryosystems, laser systems, and other IVF laboratory equipment.

Step 2: Equipment demand was estimated using fertility clinic numbers, laboratory installations, equipment utilization, replacement cycles, facility expansion, and procurement information.

Step 3: Average selling prices were estimated using manufacturer disclosures, distributor quotations, equipment specifications, procurement benchmarks, and primary research.

Step 4: Market revenue was calculated using:

Number of Equipment Units Sold × Average Selling Price per Unit

Step 5: Equipment revenues were aggregated and reconciled with total instrument market estimates.

Step 6: Forecast assumptions considered new fertility laboratory openings, capacity expansion, equipment replacement, laboratory automation, imaging requirements, and investment in advanced reproductive technologies.

End-Use-Based Market Estimation

This model estimates market size based on revenues generated by facilities providing IVF treatments.

Step 1: The market was segmented into:

• Fertility Clinics

• Hospitals & Other Settings

Step 2: Facility-level data were collected from fertility clinic directories, hospital databases, ART registries, provider disclosures, company reports, and industry sources.

Step 3: IVF treatment volumes and average revenue per cycle were estimated separately for fertility clinics and hospitals & other settings using facility activity, procedure mix, laboratory capacity, treatment pricing, and primary interviews.

Step 4: End-use revenue was calculated using:

Number of IVF Treatment Cycles by Setting × Average Revenue per Cycle

Step 5: Facility-level estimates were aggregated to determine total end-use revenue and reconciled with national IVF market estimates.

Step 6: Forecast assumptions considered fertility clinic expansion, hospital-based reproductive services, patient access, availability of specialized medical staff, laboratory infrastructure, and changes in treatment volumes across care settings.

Market Validation and Forecasting

The estimates derived from the IVF treatment cycle model, instrument revenue model, culture media model, disposable device model, capital equipment model, and end-use model were cross-validated through data triangulation. Findings were further verified through primary interviews with fertility clinic operators, reproductive endocrinologists, embryologists, laboratory managers, product manufacturers, distributors, and industry consultants.

Final market forecasts were developed by evaluating historical IVF cycle volumes, infertility trends, treatment affordability, insurance coverage, procedure mix, instrument utilization, product pricing, fertility clinic expansion, and investment in reproductive medicine.

Forecast assumptions also considered changes in patient demographics, demand for donor and non-donor procedures, fresh and frozen treatment cycles, advances in embryo culture and cryopreservation, use of single-use IVF devices, equipment replacement, laboratory expansion, and changes in healthcare spending through 2033. The model incorporated product-level demand, end-use distribution, provider activity, and procedure volumes to maintain consistency between segment estimates and the overall market.

Delivered Customizations

This report has been delivered with the following In-depth customizations